Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INDV
INDV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INDV News
Investors Must Maintain Emotional Neutrality
Jun 29 2026
NASDAQ.COM
Beam Therapeutics Receives FDA Clearance for Gene-Editing Therapy
Jun 19 2026
NASDAQ.COM
Barclays Initiates Overweight Rating on Indivior Pharmaceuticals
Jun 18 2026
seekingalpha
Latest Wall Street Rating Updates
Jun 18 2026
CNBC
Indivior Executive Sells Shares Amid Strong Market Performance
Jun 14 2026
Fool
Indivior's Chief Scientific Officer Sells Shares Amid Stock Surge
Jun 14 2026
NASDAQ.COM
Indivior Pharmaceuticals Stock Investment Outlook
Jun 13 2026
Yahoo Finance
Analysis of High-Efficiency Stock Screening
Jun 03 2026
NASDAQ.COM
Divisadero Street Capital Reduces Indivior Stake
May 30 2026
Fool
Divisadero Street Capital Reduces Indivior Stake
May 30 2026
NASDAQ.COM
Madison Avenue Partners Acquires Indivior Shares
May 30 2026
NASDAQ.COM
Madison Avenue Partners Acquires Indivior Shares Worth $142.51 Million
May 30 2026
Fool
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
May 25 2026
NASDAQ.COM
Indivior's New Data Significantly Reduces Relapse Risk
May 21 2026
NASDAQ.COM
Claret Asset Management Acquires Indivior Shares Worth $23.36 Million
May 11 2026
Fool
Indivior Enters $175M Accelerated Share Repurchase Agreement with Barclays
May 04 2026
seekingalpha
Show More News
